The present invention relates to a method of determining the responsiveness of a
cancer patient to a treatment with a compound inhibiting
KRAS protein or a
mutant of a
KRAS protein, or to a treatment with a compound inhibiting the interaction between MDM2 and p53, the method comprising measuring the level of
Survivin in a first sample obtained from the patient prior to treatment with the compound, measuring the level of
Survivin in a second sample obtained from said patient during or
after treatment with the compound, comparing the level of
Survivin in said second sample with the level of Survivin in said first sample, wherein the patient is determined to be responsive to the treatment with said compound when the level of Survivin in the second sample is decreased as compared to the level of Survivin in the first sample. The present invention further relates to the use of Survivin in a method for determining the ability of a compound to inhibit
KRAS protein or a
mutant of a KRAS protein, or of a compound inhibiting the interaction between MDM2 and p53, or of a
pharmaceutical formulation comprising said compound inhibiting KRAS protein or a
mutant of a KRAS protein or said compound inhibiting the interaction between MDM2 and p53, to treat
cancer.